Skip to main content

Biparametric Quantitative MRI for Prostate Cancer Detection.

Publication ,  Journal Article
Uyanik, M; Vigneswaran, HT; Hale, GR; Gann, P; Magin, R; Abern, MR
Published in: Top Magn Reson Imaging
December 1, 2023

OBJECTIVES: This study sought to prospectively investigate a novel quantitative biparametric prostate magnetic resonance imaging (MRI) protocol to detect prostate cancer (PCa) in biopsy-naïve men. Secondarily, this study reports the accuracy of fractional order calculus (FROC) diffusion and quantitative T2 compared with the Prostate Imaging Reporting & Data System (PI-RADS). METHODS: This prospective pilot study (NCT04175730) enrolled 50 prostate biopsy-naïve men who met eligibility criteria. All men received 3T MRI with T2 and diffusion-weighted imaging (DWI) (b-values: 50-4,000 s/mm2). Men with PI-RADS lesions ≥3 underwent targeted and systematic prostate biopsy, omitting systematic biopsy cores in peripheral zone lesions. DWI series images were fit to signal decay to calculate ADC (mm2/s) and the FROC model for coefficient DF (mm2/s). The primary end point was detection of Gleason grade group ≥2 (GG≥2) PCa. Receiver operating characteristic regression and area under the curve (AUC) were reported. RESULTS: Forty-eight men underwent MRI and biopsy. Mean age was 61.5 years (56-68), 29% were White, 52% were African American, mean PSA was 6.0 ng/mL (4.9-8.0), and mean PSA density was 0.14 ng/mL2. In total, 61 PI-RADS ≥3 lesions were targeted for biopsy. GG≥2 PC was found in 7% (1/14) of PI-RADS 3 lesions, 28% (10/36) of PI-RADS 4 lesions, and 36% (4/11) of PI-RADS 5 lesions. The AUC for detection of GG≥2 PC was 0.63 (0.5-0.76) for PI-RADS, 0.82 (0.68-0.96) for ADC, and 0.87 (0.77-0.97) for the FROC model. CONCLUSION: This small prospective pilot study demonstrates the feasibility of a novel quantitative biparametic MRI protocol to detect prostate cancer in biopsy-naïve men.

Duke Scholars

Published In

Top Magn Reson Imaging

DOI

EISSN

1536-1004

Publication Date

December 1, 2023

Volume

32

Issue

6

Start / End Page

66 / 72

Location

United States

Related Subject Headings

  • Prostatic Neoplasms
  • Prostate-Specific Antigen
  • Prostate
  • Prospective Studies
  • Pilot Projects
  • Nuclear Medicine & Medical Imaging
  • Middle Aged
  • Male
  • Magnetic Resonance Imaging
  • Image-Guided Biopsy
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Uyanik, M., Vigneswaran, H. T., Hale, G. R., Gann, P., Magin, R., & Abern, M. R. (2023). Biparametric Quantitative MRI for Prostate Cancer Detection. Top Magn Reson Imaging, 32(6), 66–72. https://doi.org/10.1097/RMR.0000000000000308
Uyanik, Meltem, Hari T. Vigneswaran, Graham R. Hale, Peter Gann, Richard Magin, and Michael R. Abern. “Biparametric Quantitative MRI for Prostate Cancer Detection.Top Magn Reson Imaging 32, no. 6 (December 1, 2023): 66–72. https://doi.org/10.1097/RMR.0000000000000308.
Uyanik M, Vigneswaran HT, Hale GR, Gann P, Magin R, Abern MR. Biparametric Quantitative MRI for Prostate Cancer Detection. Top Magn Reson Imaging. 2023 Dec 1;32(6):66–72.
Uyanik, Meltem, et al. “Biparametric Quantitative MRI for Prostate Cancer Detection.Top Magn Reson Imaging, vol. 32, no. 6, Dec. 2023, pp. 66–72. Pubmed, doi:10.1097/RMR.0000000000000308.
Uyanik M, Vigneswaran HT, Hale GR, Gann P, Magin R, Abern MR. Biparametric Quantitative MRI for Prostate Cancer Detection. Top Magn Reson Imaging. 2023 Dec 1;32(6):66–72.

Published In

Top Magn Reson Imaging

DOI

EISSN

1536-1004

Publication Date

December 1, 2023

Volume

32

Issue

6

Start / End Page

66 / 72

Location

United States

Related Subject Headings

  • Prostatic Neoplasms
  • Prostate-Specific Antigen
  • Prostate
  • Prospective Studies
  • Pilot Projects
  • Nuclear Medicine & Medical Imaging
  • Middle Aged
  • Male
  • Magnetic Resonance Imaging
  • Image-Guided Biopsy